Sean Lee
Stock Analyst at HC Wainwright & Co.
(2.58)
# 1,206
Out of 4,667 analysts
65
Total ratings
28.81%
Success rate
0.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PSTV Plus Therapeutics | Reiterates: Buy | $8 | $1.19 | +572.27% | 9 | Nov 15, 2024 | |
| MYO Myomo | Reiterates: Buy | $7.5 | $4.92 | +52.44% | 4 | Nov 13, 2024 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $6 → $22 | $19.00 | +15.79% | 8 | Nov 11, 2024 | |
| CTSO Cytosorbents | Reiterates: Neutral | $1 | $0.92 | +9.18% | 11 | Nov 11, 2024 | |
| ATEC Alphatec Holdings | Reiterates: Buy | $20 | $9.93 | +101.41% | 10 | Oct 31, 2024 | |
| VSTM Verastem | Reiterates: Buy | $7 | $3.79 | +84.70% | 11 | Oct 18, 2024 | |
| KZIA Kazia Therapeutics | Reiterates: Buy | $20 | $5.61 | +256.51% | 4 | Jul 12, 2024 | |
| CASI CASI Pharmaceuticals | Maintains: Buy | $12 → $6 | $5.26 | +14.07% | 7 | May 15, 2024 | |
| AKTX Akari Therapeutics, | Initiates: Buy | $30 | $1.47 | +1,940.82% | 1 | Dec 5, 2022 |
Plus Therapeutics
Nov 15, 2024
Reiterates: Buy
Price Target: $8
Current: $1.19
Upside: +572.27%
Myomo
Nov 13, 2024
Reiterates: Buy
Price Target: $7.5
Current: $4.92
Upside: +52.44%
Monopar Therapeutics
Nov 11, 2024
Maintains: Buy
Price Target: $6 → $22
Current: $19.00
Upside: +15.79%
Cytosorbents
Nov 11, 2024
Reiterates: Neutral
Price Target: $1
Current: $0.92
Upside: +9.18%
Alphatec Holdings
Oct 31, 2024
Reiterates: Buy
Price Target: $20
Current: $9.93
Upside: +101.41%
Verastem
Oct 18, 2024
Reiterates: Buy
Price Target: $7
Current: $3.79
Upside: +84.70%
Kazia Therapeutics
Jul 12, 2024
Reiterates: Buy
Price Target: $20
Current: $5.61
Upside: +256.51%
CASI Pharmaceuticals
May 15, 2024
Maintains: Buy
Price Target: $12 → $6
Current: $5.26
Upside: +14.07%
Akari Therapeutics,
Dec 5, 2022
Initiates: Buy
Price Target: $30
Current: $1.47
Upside: +1,940.82%